SEARCH

SEARCH BY CITATION

References

  • 1
    Durham SR. Mechanisms of mucosal inflammation in the nose and lung. Clin Exp Allergy 1998;28:1116.
  • 2
    International Study of Asthma and Allergies in Childhood (ISAAC). Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis and atopic eczema. Lancet 1998;351:12251232.DOI: 10.1016/s0140-6736(97)07302-9
  • 3
    Sly RM. Changing prevalence of allergic rhinitis and asthma. Ann Allergy Asthma Immunol 1999;82:233248.
  • 4
    Ciprandi G, Vizzaccaro A, Cirillo I, Crimi P, Canonica GW. Increase of asthma and allergic rhinitis prevalence in young Italian men. In Arch Allergy Immunol 1996;111:278283.
  • 5
    Lund V, Aaronson D, Bousquet J, et al. International consensus report on the diagnosis and management of rhinitis. Allergy 1994;49 Suppl 19:534.
  • 6
    Bousquet J, Bullinger M, Fayol C, et al. Assessment of quality of life in patients with perennial allergic rhinitis with the French version of the SF-36 HS questionnaire. J Allergy Clin Immunol 1994;94:182188.
  • 7
    Van Cauwenberge P, Bachert C, Passalacqua G, et al. Consensus statement on the treatment of allergic rhinitis. Allergy 2000;55:116134.DOI: 10.1034/j.1398-9995.2000.00526.x
  • 8
    Ciprandi G, Ricca V, Tosca MA, Landi M, Passalacqua G, Canonica GW. Continuous antihistamine treatment controls allergic inflammation and reduces respiratory morbidity in children with mite allergy. Allergy 1999;55:358365.
  • 9
    Ciprandi G, Passalacqua G, Mincarini M, Ricca V, Canonica GW. Continuous versus on demand treatment with cetirizine for allergic rhinitis. Ann Allergy Asthma Immunol 1997;79:507515.
  • 10
    Ciprandi G, Passalacqua G, Canonica GW. Effects of H1 antihistamines on adhesion molecules: a possible rationale for long-term treatment. Clin Exp Allergy 1999;29 Suppl 3:4953.
  • 11
    Corren J. The impact of allergic rhinitis on bronchial asthma. J Allergy Clin Immunol 1998;101:352356.
  • 12
    Corren J, Adinoff AD, Buckmeier AD, Irvin CG. Nasal beclomethasone prevents the seasonal increase in bronchial hyperresponsiveness in patients with allergic rhinitis and asthma. J Allergy Clin Immunol 1992;90:250256.
  • 13
    Watson WTA, Becker AB, Simons FER. Treatment of allergic rhinitis with intranasal corticosteroids in patients with mild asthma, effect on lower airways responsiveness. J Allergy Clin immunol 1993;91:97101.
  • 14
    National Institutes of Health. Global strategy for asthma management and prevention. WHO/NHLBI workshop report. Publication no. 95–3659; Jan 1995.
  • 15
    Weiner JM, Abramson MJ, Puy RM. Intranasal corticosteroids vs oral H1 receptor antagonists in allergic rhinitis: systematic review of randomized controlled trials. BMJ 1998;317:16241629.
  • 16
    Onrust SV, Lamb HM. Mometasone furoate. A review of its intranasal use in allergic rhinitis. Drugs 1998;56:725745.
  • 17
    Ricca V, Landi M, Ferrero P, et al. Minimal persistent inflammation is also present in patients with seasonal allergic rhinitis. J Allergy Clin Immunol 2000;105:5457.
  • 18
    Foresi A, Pelucchi A, Gherson G, Mastropasqua B, Chiapparino A, Testi R. Once daily intranasal fluticasone propionate reduces nasal symptoms and inflammation but also attenuates the increase in bronchial responsiveness during the grass pollen season in allergic rhinitis. J Allergy Clin Immunol 1996;98:274282.
  • 19
    Simons FER. Allergic rhinobronchitis: the asthma-allergic rhinitis link. J Allergy Clin Immunol 1999;104:534540.